-
Study aim
-
The effect of cabergoline on insulin resistance in patients with IGT using HOMA-IR model and comparison with placebo
-
Design
-
A randomized, blinded and parallel groups trial. Randomization was done with simple randomization method
-
Settings and conduct
-
The recruitment of patients will be done in Ayatolah Taleghani Hospital, Tehran, Iran. All Participants, Investigators, Outcome assessors, Data analyst and quality controller are blinded
-
Participants/Inclusion and exclusion criteria
-
Adult Patients (20-65 years) who were diagnosed as impaired fasting glucose and/or impaired glucose tolerance were included in this study, who had a history of severe hepatic failure (Child-Pugh scores of 10 or higher), history of pulmonary, pericardial, cardiac valvular, or retroperitoneal fibrotic disorders, history of hypersensitivity reaction to ergot derivatives, those with uncontrolled hypertension, diagnosed diabetes, major psychiatric disorders, bulimia or/and anorexia nervosa, pregnant or nursing mothers and those who are receiving medications which affect prolactin secretion, were excluded from this study.
-
Intervention groups
-
Test Group: 15 tablets of cabergoline 0.5 mg
Placebo Group: 15 tablets of placebo with similar shape and color
-
Main outcome variables
-
The main outcomes of the study is fasting plasma glucose, 2h plasma glucose, Hb A1c, 2h insulin, weight, wrist circumference and body mass index.